Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80
Document › Details

BiondVax Pharmaceuticals Ltd.. (1/28/21). "Press Release: BiondVax Announces Third Quarter 2020 Financial Results & Business Update". Jerusalem.

Organisations Organisation BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)
  Organisation 2 European Investment Bank (EIB)
  Group EU (govt)
Products Product M-001 universal flu vaccine (BiondVax)
  Product 2 anti-infective drug
Persons Person Reichman, Amir (BiondVax 202103– CEO before GSK Vaccines + Novartis Vaccines + NeuroDerm)
  Person 2 Phillipson, Joshua E. (BiondVax 201707 Business Development Manager)
     


   
Record changed: 2021-02-04

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top